“…A vaccine conjugated with tetanus toxoid (TT) causes lower antibody levels and seroconversion rate in children with GA <32 weeks observed until the age of 5 than in premature infants even after 3 administrations (at 3, 4 and 5 months of age). However, the authors emphasize that the vaccination has protective effect for this group, too [37]. It appears that the shortened primary immunization does not produce sufficient results in small premature infants, while almost all children, including premature infants with GA ≤29 weeks, developed protective antibody levels after 3 administrations of a CRM 197 -conjugate vaccine with at 2, 4 and 6 months of age [33].…”